New research shows that inhibition of the CECR2 gene prevents the progression or metastasis of triple-negative breast cancer.
A study by scientists at the Yale Cancer Center shows that inhibition of the CECR2 gene prevents the progression or metastasis of triple negative breast cancer. The discovery is an early step in the search for new drugs for triple negative breast cancer (TNBC), one of the most difficult subtypes to treat. The discovery was published in the journal Science Translational Medicine.
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
